Mink therapeutics to participate in h.c. wainwright global investment conference

New york, sept. 03, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that dr. jennifer buell, chief executive officer, will participate in a fireside chat and investor one-on-ones at the upcoming h.c. wainwright 26th annual global investment conference on september 9-11th. the fireside chat will take place at 7:00 a.m. et on monday, september 9th.
INKT Ratings Summary
INKT Quant Ranking